Aytu BioPharma (NASDAQ:AYTU) First Quarter 2025 Results

Key Financial Results

• Revenue: US$16.6m (down 25% from 1Q 2024).
• Net income: US$1.09m (up from US$8.12m loss in 1Q 2024).
• Profit margin: 6.6% (up from net loss in 1Q 2024).
• EPS: US$0.18 (up from US$1.48 loss in 1Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Aytu BioPharma Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 20%. Earnings per share (EPS) also surpassed analyst estimates.

Looking ahead, revenue is expected to decline by 7.4% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 10%.

Performance of the American Pharmaceuticals industry.

The company's shares are down 5.5% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Aytu BioPharma (1 is a bit unpleasant) you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.